Medplus Health Services pledge date corrected to July 24, 2026

Catalyst Trusteeship Limited has rectified its regulatory disclosure regarding the creation of a pledge over 49,00,000 equity shares of medplus health services , correcting the date of acquisition from June 24, 2026, to July 24, 2026. The revised filing, submitted to the National Stock Exchange of India Limited and BSE Limited on July 31, 2026, clarifies that the encumbrance was created on July 24, not June 24, as initially reported on July 28, 2026. This correction ensures accurate record-keeping for debenture holders and market participants monitoring significant shareholding changes.

The disclosure was made pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Deesha Srikanth, Senior Vice President at Catalyst Trusteeship Limited, signed the rectification notice from Mumbai. The trustee acts on behalf of debenture holders and is not part of the promoter group of Medplus Health Services Limited. The mode of acquisition remains unchanged as "by way of creation of pledge over shares."

Revised Pledge Details

The correction affects only the timeline of the transaction; all quantitative figures remain identical to the initial report. Prior to this specific pledge, Catalyst Trusteeship held an encumbrance over 1,58,50,400 shares, representing 13.19% of the total share capital. The addition of 49,00,000 shares increases the total encumbered holding to 2,07,50,400 shares.

Metric	Before Pledge	New Pledge	After Pledge
Encumbered Shares	1,58,50,400	49,00,000	2,07,50,400
% of Total Capital	13.19%	4.08%	17.27%
% of Diluted Capital	13.18%	4.08%	17.26%

The total number of shares encumbered with the acquirer now stands at 2,07,50,400, constituting 17.27% of the total share/voting capital and 17.26% of the total diluted share/voting capital. No shares carrying voting rights were acquired or sold; the change reflects solely the creation of the pledge.

Capital Structure Context

The equity share capital of Medplus Health Services Limited remains unchanged at Rs. 24,02,74,122, comprising 12,01,37,061 equity shares with a face value of Rs 2 each. The total diluted share/voting capital is recorded at Rs. 24,04,75,502, corresponding to 12,02,37,751 equity shares assuming full conversion of outstanding convertible securities or warrants. The rectification does not alter these capital metrics.

What the Numbers Show

The primary impact of this filing is procedural accuracy rather than a change in financial exposure. With nearly 17.3% of the company's voting power encumbered in favor of debenture trustees, the security position for existing debt holders remains robust. The correction from June 24 to July 24 aligns the regulatory record with the actual execution date of the pledge, ensuring transparency for investors tracking institutional financing activities. Since Catalyst Trusteeship is not part of the promoter group, these pledges are indicative of institutional debt structuring rather than promoter liquidity constraints.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.86%	-6.25%	-19.38%	-22.80%	-19.33%	-41.44%

MedPlus Health Services Limited disclosed on July 26, 2026, that its subsidiary, Optival Health Solutions Private Limited, has received a suspension order for a drug license in Karnataka. The regulatory action affects a single store located at Busstand Road, Bijapur, and carries a quantifiable financial impact, with the company estimating a potential revenue loss of ₹0.29 lacs. This incident highlights operational compliance risks within the pharmacy chain’s network, although the limited duration and monetary value suggest contained immediate consequences.

The order was issued by the Assistant Director, Drugs Control Administration, Vijayapura Circle, Vijayapura, Karnataka. The authority cited violations under Rule 65 of the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. MedPlus received the communication on July 25, 2026, and subsequently filed the disclosure with the stock exchanges to comply with transparency norms.

Regulatory and Financial Details

The disclosure was made pursuant to Regulation 30 read with Para A Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It also references SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026. The specific details of the action are outlined below:

Authority	Action Taken	Date of Receipt	Violation Details	Financial Impact
Assistant Director, Drugs Control Administration, Vijayapura Circle, Vijayapura, Karnataka	Suspension of Drug License for two days for store at Busstand Road, Bijapur	July 25, 2026	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Potential Revenue Loss of ₹0.29 lacs

The Company Secretary and Compliance Officer, Shrenik Soni, signed the filing, confirming the information is available on the company’s website as well as those of the BSE and NSE. The brief two-day suspension indicates a procedural or minor compliance lapse rather than a systemic failure, given the low financial exposure.

What the Numbers Show

The estimated revenue loss of ₹0.29 lacs is negligible relative to the overall scale of MedPlus Health Services Limited’s operations, suggesting that this isolated incident will not materially affect the consolidated financial results. However, it underscores the importance of strict adherence to local drug control regulations across all franchise and owned stores. The specificity of the violation—Rule 65 of the Drugs and Cosmetics Act—typically relates to conditions of storage or sale, implying a need for targeted operational review at the affected location rather than a broad strategic overhaul.